CDT signs SAFE note with Pep'd to expand US peptide market exposure

FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia

Astellas doses first patient in Phase 3 study of ASP2138

Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia

United Therapeutics wins FDA acceptance for ralinepag PAH filing

Takeda wins Japan approval for ORZEYFUL to treat underlying cause of narcolepsy type 1

Acadia wins EU approval for DAYBU as first treatment for Rett syndrome

Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe

GSK's Jemperli wins FDA priority review for advanced rectal cancer

GSK secures first global approval for Hibsago in Japan

Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321

Rznomics joins Lilly Gateway Labs to accelerate RNA therapeutics

Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types

CureGene commences dosing in Phase I trial of CG-0416

Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline